This glossary explains specialized terms that come up on CMT Blog: medical and genetic vocabulary, research and drug-development jargon, the organizations in the CMT world, and a few words from disability culture. Each entry gives a short, plain-language definition with its sources, then links to posts where the term comes up. Definitions are kept cautious, and where experts disagree, the entry says so. This is general information, not medical advice. For an introduction, start with What Is CMT?, and for clinics, programs, and support in Canada, see CMT Resources in Canada. For the expert databases and references that clinicians and researchers use, see CMT Data Sources and Expert References.
Jump to: A · B · C · D · E · F · G · H · I · K · L · M · N · O · P · Q · R · S · T · U · V · W · X
A
Accelerated Approval
An FDA program that lets a drug for a serious condition be approved on the basis of a surrogate endpoint, such as a blood or imaging marker, that is reasonably likely to predict a real benefit to patients, before that benefit has been shown. The company then has to run confirmatory trials, and the FDA can withdraw the approval if they don’t confirm the benefit.1 On the blog: Faster, Less Predictable: What the FDA’s Turbulent Years Mean for CMT.
Ankle-Foot Orthosis (AFO)
A brace worn on the lower leg and foot that holds the ankle and foot in position and helps with foot drop. NINDS lists braces and other orthopedic devices among the things that can help people manage CMT symptoms.2 On the blog: CMT Resources in Canada.
Antisense Oligonucleotide (ASO)
A short, synthetic strand of DNA or RNA that binds to a specific RNA message and blocks it from being used to make a protein.3 In CMT1A research, ASOs that lower PMP22 production reversed features of the disease in rats and mice; that is an animal result, not a human treatment.4 On the blog: One Patient, One Drug—and a Possible Voucher; The State of Research for Cures (2019).
Atrophy
Wasting of muscle. In CMT, the muscles served by damaged peripheral nerves, especially in the feet, legs, and hands, gradually shrink and weaken.5 On the blog: New Gene (PSAT1) Linked to Treatable CMT-like Outcomes; Differential Diagnosis with Dr. ChatGPT in the House.
Autonomic Nervous System
The part of the nervous system that runs things we don’t consciously control, such as heart rate, blood vessels, digestion, and sweating.6 GeneReviews treats hereditary sensory and autonomic neuropathy (HSAN), in which these nerves are prominently affected, as a diagnosis separate from CMT.7 On the blog: Three “Treatable CMT” Stories, and What the Market Taught Us; Differential Diagnosis with Dr. ChatGPT in the House.
Autosomal Dominant
An inheritance pattern in which one altered copy of a gene on a non-sex chromosome is enough to cause a condition.8 Most CMT is inherited this way: each child of an affected parent has a 50% chance of inheriting the variant, though some people have a new (de novo) variant that neither parent carries.9 On the blog: Genetic Cause of CMT2 Discovered?.
Autosomal Recessive
An inheritance pattern in which a condition appears only when both copies of a gene are altered (“biallelic”).10 Parents are usually unaffected carriers, and each of their children has a 25% chance of being affected. SORD neuropathy and CMT4 are recessive.11 On the blog: A New Genetic Cause of a Previously Unknown Subtype of CMT2; Three “Treatable CMT” Stories, and What the Market Taught Us.
Axonal
Describes nerve damage that mainly affects the axon, the long fibre that carries a nerve signal.12 In the traditional CMT scheme, “axonal” types (CMT2) have motor nerve conduction velocities above about 45 m/s.13 As this blog has argued, demyelinating types involve axonal loss too. On the blog: All types of CMT are “Axonal”; The State of Research for Cures (2019).
B
Bilevel Positive Airway Pressure (BiPAP)
A breathing machine that blows air through a mask at two pressures: a higher one when you breathe in and a lower one when you breathe out. A CPAP machine gives the same pressure both ways. BiPAP is a trade name; the generic term is BPAP. It’s a form of non-invasive ventilation, used when someone can breathe on their own but isn’t getting enough oxygen or can’t clear carbon dioxide.14 Small reports describe people with CMT treated with continuous or bilevel pressure for sleep apnea and breathing problems, though there isn’t yet enough evidence for screening recommendations.15 Canada’s home ventilation guideline covers non-invasive ventilation at home, with sections on ALS, the muscular dystrophies, and other conditions.16 See also Obstructive Sleep Apnea and Respiratory Muscle Weakness. On the blog: CMT, COVID-19, and Respiratory Health; Sleep Apnea and CMT.
Blinding (Single- and Double-Blind)
Keeping people in a trial from knowing who is getting the treatment and who is getting the placebo. In a single-blind study, only the researchers know.17 In a double-blind study, neither the participants nor the researchers know until the trial is over. Blinding makes the results less likely to be skewed by anything other than the treatment itself.18 An open-label study is the opposite: everyone knows. See also Randomized Controlled Trial. On the blog: Three “Treatable CMT” Stories, and What the Market Taught Us; Second Phase 3 Clinical Trial for CMT1A “Pleodrug”.
C
Canadian Neuromuscular Disease Registry (CNDR)
A Canada-wide registry of people diagnosed with neuromuscular diseases, used to connect patients with research and clinical trials.19 On the blog: CMT Resources in Canada.
Charcot-Marie-Tooth Disease (CMT)
A group of inherited disorders that damage the peripheral nerves controlling movement and sensation, usually causing slowly progressive weakness, wasting, and sensory loss in the feet, legs, and hands.20 It is the most common inherited neuropathy, affecting about 1 in 2,500 people, and variants in dozens of genes can cause it.21,22 The name comes from the three physicians who first described it, and its boundaries are still debated. On the blog: What Is CMT?; The Problem With Writing About CMT.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
An acquired, immune-related disorder that damages the myelin of peripheral nerves, causing progressive weakness and reduced sensation in the arms and legs. Unlike CMT, it is treated with steroids and other immune-focused therapies, which is why telling the two apart matters.23 On the blog: CIDP and CMT; Diagnostic Pathways for Idiopathic Neuropathy.
ClinGen (Clinical Genome Resource)
A program funded by the US National Institutes of Health that rates how strong the evidence is that a gene causes a disease, and sets standards for interpreting genetic variants. The work is done by expert panels, including one for Charcot-Marie-Tooth disease. Its ratings run from Definitive through Strong, Moderate and Limited, to Disputed.24 On the blog: Open CMT Gene Table.
Clinical Trial
A research study that tests how well new medical approaches work in people, including new ways to screen for, prevent, diagnose, or treat a disease. Also called a clinical study.25 New drugs are usually tested in phases, and the strongest designs are randomized and placebo-controlled. On the blog: Maybe it will work on CMT..?; ACE-083 Trials Miss Their Functional Goals. Tag: Clinical Trials.
CMT Association (CMTA)
A US-based nonprofit (501(c)(3)) charity whose stated mission is to support new CMT treatments, improve quality of life and pursue a cure.26 It funds the Inherited Neuropathy Consortium. This blog’s “Sunlight on the CMTA” series examines its finances and influence.27 Tag: CMTA.
CMT Exam Score (CMTES)
The clinical examination part of the CMT Neuropathy Score, without the nerve conduction measures.28 A Rasch-modified version (CMTES-R) was developed to make the score more sensitive to change over time in trials.29 On the blog: Physical Assessments for CMT; Maybe it will work on CMT..?.
CMT Functional Outcome Measure (CMT-FOM)
A performance-based scale for adults with CMT1A that tests strength, arm and leg function, balance and mobility, scored from 0 to 100. It was designed as a clinical outcome assessment for drug trials.30 On the blog: Physical Assessments for CMT; Three “Treatable CMT” Stories, and What the Market Taught Us.
CMT Health Index (CMT-HI)
A patient-reported questionnaire that measures the burden of CMT across 18 themes chosen from what people with CMT said affected their lives most. It is a copyrighted instrument of the University of Rochester.31 On the blog: Physical Assessments for CMT; Three “Treatable CMT” Stories, and What the Market Taught Us.
CMT Neuropathy Score (CMTNS)
A composite score of symptoms, examination findings and nerve conduction tests used to rate CMT severity and to measure change in natural history studies and treatment trials. Its second version (CMTNSv2) was published in 2011.32 On the blog: Physical Assessments for CMT; CMT and Respiratory Dysfunction.
CMT1
The traditional label for autosomal dominant, demyelinating CMT, with motor nerve conduction velocities below about 35 m/s. Symptoms usually start between ages 5 and 25.33,34 On the blog: All types of CMT are “Axonal”. Tag: CMT1.
CMT1A
The most common type of CMT, caused by an extra copy (duplication) of the PMP22 gene. GeneReviews says it accounts for as much as half of all CMT.35,36 On the blog: New Genetic Diagnostics for CMT; Three “Treatable CMT” Stories, and What the Market Taught Us. Tag: CMT1A.
CMT2
The traditional label for axonal CMT, with motor nerve conduction velocities above about 45 m/s. Many different genes cause it, and NINDS says it is less common than CMT1.37,38 On the blog: A New Genetic Cause of a Previously Unknown Subtype of CMT2; The State of Research for Cures (2019). Tag: CMT2.
CMT2A and MFN2
CMT2A is an axonal form of CMT caused by variants in MFN2, a gene for mitofusin 2, a protein that controls how mitochondria (the cell’s energy producers) fuse and change shape.39 It can be inherited in a dominant or recessive pattern.40 Some older papers used “CMT2A” for a proposed KIF1B association instead, which ClinGen now rates Disputed. On the blog: The State of Research for Cures (2019); Genetic Cause of CMT2 Discovered?.
CMT4
The traditional label for autosomal recessive, mostly demyelinating forms of CMT, such as those caused by GDAP1 and SH3TC2. NINDS describes CMT4 as rare and often severe.41,42 On the blog: The State of Research for Cures (2019).
CMTX
CMT caused by variants in genes on the X chromosome, usually GJB1, which makes connexin 32, a protein that forms channels between cells and is found in the Schwann cells that make myelin.43 NINDS calls CMTX the second most common form of CMT. Women can be affected too, sometimes as severely as men.44,45 On the blog: All types of CMT are “Axonal”; Genetic Cause of CMT2 Discovered?. Tag: CMTX.
Complete Response Letter (CRL)
The letter the FDA sends when it decides it can’t approve a drug or biologic application in its present form. It describes the problems the agency found and, where it can, recommends what the company could do to fix them.46 These letters used to be mostly private. Since July 2025 the FDA has been publishing many of them.47 On the blog: Faster, Less Predictable: What the FDA’s Turbulent Years Mean for CMT.
Crip Time
A concept from disability studies for the different relationship to time that disabled people live with: more time needed, unpredictable time, and schedules built around bodies rather than the clock. Alison Kafer’s Feminist, Queer, Crip describes crip time as bending the clock to meet disabled bodies and minds; Ellen Samuels explored it further in “Six Ways of Looking at Crip Time.”48,49 On the blog: Crip Time.
CRISPR
A technology that lets scientists selectively edit the DNA of living organisms.50 CMT researchers are testing it in the lab, for example to reduce PMP22 activity in CMT1A. On the blog: The State of Research for Cures (2019).
D
Demyelinating
Describes nerve damage that mainly affects myelin, the insulating sheath that helps signals travel quickly along a nerve.51 In the traditional CMT scheme, “demyelinating” types (CMT1 and CMT4) have motor nerve conduction velocities below about 35 m/s.52 On the blog: All types of CMT are “Axonal”; Diagnostic Pathways for Idiopathic Neuropathy.
Disability Justice
A framework developed by disabled activists, including the performance project Sins Invalid, that treats disability as bound up with race, gender, class, and other forms of oppression. Its ten principles begin with intersectionality and the leadership of those most affected.53 On the blog: Crip Time.
Disability Tax Credit (DTC)
A non-refundable federal tax credit for Canadians with a severe and prolonged impairment, applied for with Form T2201.54 Being approved for it opens the door to several other federal disability benefits. On the blog: CMT Resources in Canada.
Disease
A general term for an abnormal condition of the body or mind. MeSH, the US National Library of Medicine’s medical vocabulary, defines a disease as “a definite pathologic process with a characteristic set of signs and symptoms,” whose “etiology, pathology, and prognosis may be known or unknown.”55 In the ontologies that link disease records across medical databases, a disease is a tendency to undergo harmful (pathological) processes that exists because of one or more disorders in the body.56,57 On that view, an abnormal physical feature, such as mutated DNA, is the physical basis of a disease rather than an alternative to one; the paper that set out these definitions counts Tay-Sachs disease and Down syndrome among genetic diseases.58 See also Disorder, Rare Disease and SORD Neuropathy. On the blog: The “First Treatable CMT Disease” is Neither CMT Nor a Disease; Disease, Depression, and Family Denial.
Disorder
In everyday medical writing, usually a synonym for disease. The NCI Thesaurus files “disease,” “disorder” and “condition” under a single concept: “any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person.”59 Writing about CMT mixes the terms freely: MedlinePlus describes Charcot-Marie-Tooth disease as “a group of disorders,” and GeneReviews calls it a hereditary neuropathy.60,61 Some medical ontologies draw a sharper line, using disorder for the abnormal part of the body, such as mutated DNA, and disease for the tendency to harm that it creates.62 A syndrome is different again: a recognizable pattern of signs and symptoms, “a characteristic symptom complex” in MeSH’s words, whatever its cause.63 See also Disease. On the blog: The “First Treatable CMT Disease” is Neither CMT Nor a Disease; New Gene (PSAT1) Linked to Treatable CMT-like Outcomes.
Distal Hereditary Motor Neuropathy (dHMN)
Inherited neuropathies that cause weakness and wasting in the hands and feet with little or no sensory loss. Because the same genes can cause dHMN and motor forms of CMT, GeneReviews argues they should not be classified apart; others still separate them.64,65 On the blog: The “First Treatable CMT Disease” is Neither CMT Nor a Disease; The “first treatable” form of CMT?.
Drug Repurposing
Finding new uses for drugs that are already approved or in development for something else, also called repositioning. It can save time and money, but a drug that works for one disease still has to be proven in trials for another.66 On the blog: Three “Treatable CMT” Stories, and What the Market Taught Us.
Duplication
A type of genetic change in which an extra copy of a gene or chromosome segment is made.67 A duplication of PMP22 causes CMT1A, so testing for it is the usual first genetic test for CMT.68 On the blog: New Genetic Diagnostics for CMT.
E
Electromyography (EMG)
A test that uses a fine needle electrode in a muscle to record its electrical activity, showing how healthy the muscle and the nerves that control it are. It is usually done along with nerve conduction studies.69 On the blog: CMT Resources in Canada; All types of CMT are “Axonal”.
Endpoint
A measurable outcome used in a clinical trial to judge whether a treatment works. A trial names its primary endpoint in advance; when a drug “misses its primary endpoint,” the trial did not show the benefit it was designed to detect.70 On the blog: Three “Treatable CMT” Stories, and What the Market Taught Us; The “First Treatable CMT Disease” is Neither CMT Nor a Disease.
Exome Sequencing
Reading the protein-coding parts of all genes (the exome, about 1.5% of the genome).71 GeneReviews suggests it for CMT when PMP22 testing and a multigene panel have found no cause.72 On the blog: New Genetic Diagnostics for CMT.
F
Foot Drop
Weakness or paralysis of the muscles that lift the front of the foot, so the toes drag or catch when walking. It is common in CMT.73 On the blog: SIIT and CMT; Physical Assessments for CMT.
G
Gene Therapy
A treatment that works by changing a person’s genes, for example by adding a working copy of a gene, switching off a harmful one, or introducing a new gene.74,75 Gene therapies can be delivered by modified viruses or by plasmid DNA.76 As of October 2026, none has been approved for CMT. On the blog: Maybe it will work on CMT..?; The State of Research for Cures (2019).
GeneReviews
An expert-authored, peer-reviewed clinical reference on genetic conditions, published on the US National Library of Medicine’s NCBI Bookshelf. Its CMT overview is the standard starting point for CMT types, genes and testing.77 On the blog: What Is CMT?; The “First Treatable CMT Disease” is Neither CMT Nor a Disease.
Genetic Counsellor
A health professional trained to help people understand genetic test results, inheritance and family risk.78 Because CMT results are complex, GeneReviews recommends referral to a neurogenetics centre or a genetic counsellor who specializes in neurogenetics.79 On the blog: CMT Resources in Canada.
Genetics and Genetic Testing
Genetics is the branch of biology that studies inheritance, including how genes, DNA variation, and the environment interact.80 Genetic testing uses a laboratory test to look for variations in a person’s DNA. In medical care, results can confirm or rule out a suspected genetic disease and help estimate the chance of passing a variant on to children.81 For CMT, see also Multigene Panel, Exome Sequencing and Variant of Uncertain Significance. On the blog: New Genetic Diagnostics for CMT; New Study of Genetic Causes of CMT Needs Participants. Tag: Genetics.
H
Hammer Toe
A toe bent at its middle joint into a claw-like position. Tight shoes are the usual cause in the general population, but nerve problems can also cause it.82 NINDS lists hammer toes and high arches among the foot deformities of CMT.83
Hereditary Motor and Sensory Neuropathy (HMSN)
An older medical name for CMT, still used as a synonym.84 On the blog: What Is CMT?; The “First Treatable CMT Disease” is Neither CMT Nor a Disease.
Hereditary Neuropathy Foundation (HNF)
A US-based CMT nonprofit, active since 2001, that now presents itself as “HNF / CureCMT.” It runs the GRIN patient registry and a CMT biobank, and convened the FDA’s first Patient-Focused Drug Development meeting for CMT in 2018.85 On the blog: Three “Treatable CMT” Stories, and What the Market Taught Us. Tag: HNF.
Hereditary Neuropathy with Liability to Pressure Palsies (HNPP)
An inherited condition in which nerves are unusually sensitive to pressure, causing repeated episodes of numbness, tingling, and weakness in one area, often after leaning or sitting in one position.86 It is usually caused by a deletion of one copy of PMP22, the opposite of the CMT1A duplication.87 Whether it belongs inside CMT or beside it depends on the classification.88
Hereditary Sensory and Autonomic Neuropathy (HSAN)
A group of inherited neuropathies that mainly affect sensory and autonomic nerves, causing loss of feeling without much weakness or wasting. GeneReviews treats HSAN as a separate diagnosis to distinguish from CMT.89
HGNC
The HUGO Gene Nomenclature Committee, which approves a unique symbol and name for each human gene, such as PMP22 or MFN2, so that labs, papers, and databases all refer to the same gene the same way.90 On the blog: Open CMT Gene Table.
I
Idiopathic Neuropathy
Neuropathy for which no cause has been found. “Idiopathic” simply means “of unknown cause.”91 On the blog: Diagnostic Pathways for Idiopathic Neuropathy.
Inherited Neuropathy Consortium (INC)
A research network dedicated to clinical research on the different forms of CMT, with its administrative centre at the University of Iowa. Its website describes it as a previously funded consortium of the NIH’s Rare Diseases Clinical Research Network and says it is funded by the CMTA.92 On the blog: A New Genetic Cause of a Previously Unknown Subtype of CMT2.
Intermediate CMT
CMT with motor nerve conduction velocities between the demyelinating and axonal ranges, roughly 35–45 m/s.93 Some researchers argue that many “intermediate” cases are better understood as axonal.94 On the blog: All types of CMT are “Axonal”; The “first treatable” form of CMT?.
K
KIF1A
A gene that makes a kinesin, a motor protein that carries cargo along the long fibres (axons) of nerve cells.95 Changes in KIF1A cause a group of conditions called KIF1A-associated neurologic disorders (KAND). GeneReviews describes four: a complex neurodevelopmental form, a simpler form, a form of hereditary sensory and autonomic neuropathy (HSAN), and a form of ALS. What they share is progressive degeneration of nerve cells.96
KIF1B
A gene for a kinesin motor protein that carries cargo along the long fibres (axons) of nerve cells. In 2001 a variant in KIF1B in one Japanese family with axonal CMT led to the label CMT2A1. In October 2026 the ClinGen Charcot-Marie-Tooth expert panel rated the KIF1B and CMT2A1 link Disputed, because the evidence rested on a single family and MFN2 had not been excluded. That is a statement about the gene-disease link, not about anyone’s neuropathy. For the current rating, see the Open CMT Gene Table.
Knee-Ankle-Foot Orthosis (KAFO)
A brace that extends an ankle-foot orthosis up the thigh to support the knee as well. Ankle-foot and knee-ankle-foot orthoses are both commonly used to improve walking in neuromuscular diseases. In a 2025 Dutch trial, adults with weakness in the calf muscles, the thigh muscles that keep the knee straight (quadriceps), or both, who got orthoses matched to their walking problems in an expert clinic, reached more of their personal goals than those given usual care.97 See also Foot Drop.
L
Length-Dependent Neuropathy
Nerve damage that starts farthest from the spine, in the feet and lower legs, and works its way up and into the hands. Both demyelinating and axonal forms of CMT are thought of as length-dependent. By the time sensory loss reaches the knees, it often starts in the hands too, in the classic “stocking–glove” pattern.98 See also Peripheral Neuropathy, Axonal and Demyelinating. On the blog: Physical Assessments for CMT.
A national network, based in Ottawa, linking neuromuscular researchers, clinicians, and patients in Canada. Its Canadian Neuromuscular Clinical Trial Network aims to make Canadian sites ready to run trials.99 On the blog: CMT Resources in Canada; Three “Treatable CMT” Stories, and What the Market Taught Us.
M
Mondo Disease Ontology (Mondo)
An open classification of about 23,000 human diseases that merges and cross-references disease terms from OMIM, Orphanet and other sources, so one ID stands for the same disease across all of them. Mondo isn’t an acronym: the name comes from the Latin mundus, “world,” because the project aims to harmonize disease definitions around the world. Only its IDs are written in capitals, with the prefix Mondo, as in MONDO:0000001. It is a source of newer disease names alongside the old CMT types, and it supplies the subtype names in the Open CMT Gene Table.100 On the blog: Open CMT Gene Table.
Multigene Panel
A genetic test that checks many genes linked to a condition at once. For CMT, GeneReviews recommends a panel that includes the eight most commonly involved genes once PMP22 testing is negative.101 On the blog: New Genetic Diagnostics for CMT; The “First Treatable CMT Disease” is Neither CMT Nor a Disease.
Muscular Dystrophy Canada (MDC)
A Canadian charity that serves people with all neuromuscular disorders, not only muscular dystrophy, so it includes people with CMT.102 On the blog: CMT Resources in Canada.
N
Natural History Study
A study that follows people with a condition over time, without an experimental treatment, to learn how it develops.103 For rare diseases such as CMT, this information is often missing, and the FDA encourages such studies to support drug development.104 ACT-CMT, which follows adults with CMT1A to validate outcome measures, is one example.105 On the blog: Three “Treatable CMT” Stories, and What the Market Taught Us.
Nerve Conduction Study (NCS) and Velocity (NCV)
A test that uses small electrical pulses on the skin to measure how fast signals travel along a nerve.106 Motor conduction velocity is the basis of the traditional split between demyelinating, intermediate and axonal CMT.107 On the blog: All types of CMT are “Axonal”; CMT Resources in Canada.
Neuromuscular Disease Network for Canada (NMD4C)
O
Obstructive Sleep Apnea (OSA)
A sleep disorder in which breathing repeatedly pauses because the airway narrows or closes during sleep. Loud snoring and daytime sleepiness are common signs.108 On the blog: Sleep Apnea and CMT; Should I play the didgeridoo (or harmonica) to fight sleep apnea‽. Tag: Sleep Apnea.
Open-Label Study
A study in which both the participants and the researchers know which treatment is being given; also called non-blinded.109 Without blinding or a comparison group, its results are harder to interpret than those of a randomized, placebo-controlled trial. On the blog: Three “Treatable CMT” Stories, and What the Market Taught Us.
Orphan Drug
A drug for a rare disease or condition. In the US, the Orphan Drug Act of 1983 lets a company ask the FDA to designate its drug as an orphan drug, which brings tax credits for clinical trials, exemption from FDA user fees and, after approval, up to seven years of market exclusivity.110 See also Rare Disease and Rare Pediatric Disease. On the blog: One Patient, One Drug—and a Possible Voucher; Faster, Less Predictable: What the FDA’s Turbulent Years Mean for CMT.
Overall Neuropathy Limitations Scale (ONLS)
A short disability scale for peripheral neuropathy that rates limitations in everyday arm and leg activities. It was adapted from the Overall Disability Sum Score in 2006.111 It was the main measure in the phase 3 trials of PXT3003 for CMT1A. On the blog: Second Phase 3 Clinical Trial for CMT1A “Pleodrug”; Physical Assessments for CMT.
P
Peripheral Neuropathy
Damage to the nerves outside the brain and spinal cord, often causing numbness, tingling, pain, or weakness that usually starts in the hands or feet.112 When many nerves are involved it is a polyneuropathy; CMT is an inherited sensorimotor polyneuropathy.113 On the blog: What Is CMT?; Diagnostic Pathways for Idiopathic Neuropathy.
Pes Cavus
A high-arched foot, one of the typical signs of CMT.114 On the blog: What Is CMT?; Differential Diagnosis with Dr. ChatGPT in the House.
Phase 1, 2, and 3 Trials
The stages of testing a new drug in people. Phase 1 studies safety and dosage in a small group; phase 2 looks for effectiveness and side effects in up to several hundred patients; phase 3 tests efficacy and monitors adverse reactions in a larger group, often hundreds to thousands.115 On the blog: Second Phase 3 Clinical Trial for CMT1A “Pleodrug”; Three “Treatable CMT” Stories, and What the Market Taught Us.
Phenotype
A person’s observable traits, including the signs and symptoms of a condition.116 In CMT, the same gene can produce different phenotypes, even within one family.117
Phrenic Nerve
The nerve that runs from the spinal cord to the diaphragm and makes it contract and relax, which helps control breathing.118 Some case reports link CMT to phrenic nerve and diaphragm weakness. On the blog: Sleep Apnea and CMT; CMT and Respiratory Dysfunction.
Placebo
An inactive substance or treatment that looks and is given the same way as the drug being tested, so the drug’s effects can be compared fairly.119 On the blog: Three “Treatable CMT” Stories, and What the Market Taught Us; ACE-083 Trials Miss Their Functional Goals.
Plasmid
A small, often circular DNA molecule. Engineered plasmids can carry therapeutic genes into human cells, as in the experimental drug Engensis.120,121 On the blog: Maybe it will work on CMT..?; Three “Treatable CMT” Stories, and What the Market Taught Us.
Plausible Mechanism Framework
An FDA approach to approving individualized treatments, such as an antisense oligonucleotide made for one patient, for genetic diseases whose cause is known. Instead of large trials, it relies on very small trials plus supporting evidence, such as what is known about the disease’s biology. The FDA set it out in draft guidance in February 2026; draft guidance is not binding.122 In 2026, CMT trial recommendations from patient charities, clinicians, and drug companies pointed sponsors to it.123 See also Antisense Oligonucleotide. On the blog: One Patient, One Drug—and a Possible Voucher; Faster, Less Predictable: What the FDA’s Turbulent Years Mean for CMT.
Pleodrug
Pharnext’s term for PXT3003, a fixed low-dose combination of three existing drugs (baclofen, naltrexone, and D-sorbitol) that was tested in CMT1A.124 On the blog: Second Phase 3 Clinical Trial for CMT1A “Pleodrug”; Three “Treatable CMT” Stories, and What the Market Taught Us.
PMP22
The gene for peripheral myelin protein 22, a component of the myelin that Schwann cells wrap around peripheral nerves. An extra copy causes CMT1A; losing one copy is the most common cause of HNPP.125 On the blog: New Genetic Diagnostics for CMT.
Priority Review Voucher
A voucher the FDA gives a company when it approves certain drugs, including qualifying drugs for rare pediatric diseases. The holder can use it to have a different drug reviewed in six months instead of the standard ten, or sell it to another company.126 A 2020 review by the US Government Accountability Office found little evidence that voucher programs changed drug development.127 See also Rare Pediatric Disease. On the blog: One Patient, One Drug—and a Possible Voucher; Faster, Less Predictable: What the FDA’s Turbulent Years Mean for CMT.
Q
Quality of Life (QoL)
A person’s overall sense of well-being and ability to carry out the activities of daily living, which clinical trials often measure.128 It’s usually captured as a patient-reported outcome: information about health that comes directly from the patient, such as symptoms and how a disease or treatment affects daily life.129 CMT research is making more use of patient-reported outcome measures, and keeping up quality of life is a central goal of long-term care.130 See also CMT Health Index and Endpoint. On the blog: ACE-083 Trials Miss Their Functional Goals; If Pain Makes You Avoid Exercise, You’ll Gain More of It.
Describes traits or conditions caused by genes on the X chromosome.131 Because of this, X-linked CMT is passed on differently to sons and daughters, and women can be affected, sometimes as severely as men.132 On the blog: Genetic Cause of CMT2 Discovered?; What Is CMT?.
R
Randomized Controlled Trial
A study in which participants are assigned by chance to different groups, such as a drug or a placebo, so the groups are similar and their outcomes can be compared fairly.133 On the blog: Three “Treatable CMT” Stories, and What the Market Taught Us; Maybe it will work on CMT..?.
Rare Disease
In the US, the Orphan Drug Act defines a rare disease as one affecting fewer than 200,000 people.134 Canada has no legal definition; Health Canada notes the Canadian Organization for Rare Disorders’ threshold of fewer than 1 in 2,000 people.135 At about 1 in 2,500 people, CMT fits both.136 On the blog: One Patient, One Drug—and a Possible Voucher; Three “Treatable CMT” Stories, and What the Market Taught Us; Differential Diagnosis with Dr. ChatGPT in the House.
Rare Pediatric Disease
In US law, a serious or life-threatening disease whose serious effects mainly appear from birth to age 18, and that is also rare under the Orphan Drug Act. The FDA can designate a drug for such a disease, and approval of a qualifying application can earn the company a priority review voucher. Congress renewed the program in February 2026, and the FDA can award vouchers until September 30, 2029.137 See also Orphan Drug and Priority Review Voucher. On the blog: One Patient, One Drug—and a Possible Voucher.
Respiratory Muscle Weakness
Weakness of the muscles that power breathing, including the diaphragm, the thin muscle below the lungs and heart that separates the chest from the abdomen.138 It is assessed with pulmonary function tests, which measure how much air the lungs can hold and how quickly air moves in and out.139 In a 2015 study of a large family with CMT2, breathing-muscle strength and lung function were lower than in healthy controls and worsened with CMT severity, even without obvious symptoms.140 See also Phrenic Nerve and Obstructive Sleep Apnea. On the blog: CMT and Respiratory Dysfunction; Respiratory Problems and CMT; CMT’s Impact on Respiration. Tag: Breathing.
S
Schwann Cell
A support cell of the peripheral nervous system that wraps around nerve fibres and makes the myelin that insulates them. Many CMT genes, including PMP22, act in Schwann cells.141,142 On the blog: The State of Research for Cures (2019).
Semidominant
A pattern of inheritance in which one changed copy of a gene can cause the condition, and two changed copies (one from each parent) can too, sometimes with a different or more severe form. In the Open CMT Gene Table, EGR2, GDAP1 and MFN2 are rated this way. See also Autosomal Dominant and Autosomal Recessive.143 On the blog: Open CMT Gene Table.
SORD Neuropathy (CMT-SORD)
An inherited neuropathy caused by variants in both copies of the SORD gene, which leave the body unable to break down sorbitol. Its discoverers called it “common and potentially treatable,” and it is often grouped with recessive CMT2 or dHMN.144,145 On the blog: The “First Treatable CMT Disease” is Neither CMT Nor a Disease; Three “Treatable CMT” Stories, and What the Market Taught Us. Tag: SORD.
Spinal Muscular Atrophy (SMA)
A genetic disorder in which the loss of motor neurons, the nerve cells that control muscle movement, causes weakness and wasting in the muscles used for movement, usually worst in those closest to the centre of the body. It is caused by variants in both copies of the SMN1 gene and inherited in an autosomal recessive pattern.146 It is not the same as “distal SMA,” a name for some motor neuropathies now often grouped with dHMN. On the blog: The State of Research for Cures (2019); Differential Diagnosis with Dr. ChatGPT in the House.
Splice Variant
A genetic variant that changes how a gene’s RNA message is spliced, the step in which non-coding stretches (introns) are cut out and the coding stretches (exons) joined. Many sit at the boundary of an exon and an intron, and they can make the cell drop part of the message or keep extra sequence, so the protein is altered or not made.147 Others lie deep inside an intron and create a new, “cryptic” splice site; an experimental antisense oligonucleotide for one person with CMT2S targets a variant of this kind.148 On the blog: One Patient, One Drug—and a Possible Voucher.
Spoon Theory
A metaphor created by Christine Miserandino, who has lupus, to explain living with limited daily energy: each task costs a “spoon,” and when they run out, you’re done. People with chronic illness sometimes call themselves “spoonies.”149 On the blog: Asking for the ADA Suite; Fuck Pain! And People Who Don’t Get It.
Surrogate Endpoint
A trial measure used as a substitute for how a patient feels, functions or survives, such as a blood level, because it is expected to predict real benefit. Regulators accept it only to the extent that evidence shows it does.150 On the blog: Three “Treatable CMT” Stories, and What the Market Taught Us; The “first treatable” form of CMT?.
T
Tendon Transfer
Surgery that reattaches a tendon in a new place to rebalance the pull of weak and strong muscles. In CMT foot deformity, weakness in muscles at the front and outer side of the lower leg lets a stronger one, the peroneus longus, overpull. Surgeons may move the posterior tibial tendon to the top of the foot to help lift it, and transfer the peroneus longus onto the weaker peroneus brevis.151 Later reconstructive surgery often combines tendon lengthening or transfer with cutting and realigning bone (osteotomy) and fusing joints (arthrodesis).152 See also Pes Cavus, Foot Drop and Hammer Toe.
Translational Research
Research that turns laboratory findings into new ways to diagnose and treat disease.153 It’s the step between results in cells and animal models and clinical trials in people. On the blog: Maybe It Will Work on CMT; CMT Research and Support Organizations in Canada that are Actually Canadian.
U
Upper and Lower Motor Neurons
The two links in the chain that moves muscles. Upper motor neurons are nerve cells in the brain. They signal lower motor neurons in the brain stem and spinal cord, which carry the message to the muscles. Damage to the upper link causes stiffness (spasticity) and overactive reflexes. When signals from the lower link to the muscles are disrupted, the muscles weaken and shrink (atrophy). Motor neuron diseases, including ALS and spinal muscular atrophy, attack these cells.154 See also Distal Hereditary Motor Neuropathy.
V
Variant of Uncertain Significance (VUS)
A genetic change that may or may not cause disease, because there isn’t enough evidence either way. A VUS can’t confirm or rule out a diagnosis; testing relatives or new research may clarify it later.155 On the blog: Late Diagnoses; CMT Resources in Canada.
W
Whole Genome Sequencing (WGS)
Reading the exact order of all the building blocks (nucleotides) in a person’s genome, their complete set of DNA, not just the protein-coding parts read in exome sequencing.156 For CMT, GeneReviews says exome sequencing is the most common choice and genome sequencing is also possible.157 See also Multigene Panel. On the blog: New Genetic Diagnostics for CMT.
X
X-Linked
Notes
- FDA, “Accelerated Approval Program.” ↩︎
- NINDS, “Charcot-Marie-Tooth Disease” (reviewed 2026). ↩︎
- NCI Dictionary of Cancer Terms, “antisense oligonucleotide.” ↩︎
- Zhao et al., “PMP22 Antisense Oligonucleotides Reverse Charcot-Marie-Tooth Disease Type 1A Features in Rodent Models,” J Clin Invest (2018), doi. ↩︎
- MedlinePlus Genetics, “Charcot-Marie-Tooth Disease.” ↩︎
- NCI Dictionary of Cancer Terms, “autonomic nervous system.” ↩︎
- Bird, “Charcot-Marie-Tooth Hereditary Neuropathy Overview,” GeneReviews (rev. 2025), NCBI Bookshelf. ↩︎
- NHGRI Talking Glossary, “Autosomal Dominant.” ↩︎
- Bird, “Charcot-Marie-Tooth Hereditary Neuropathy Overview,” GeneReviews (rev. 2025), NCBI Bookshelf. ↩︎
- NHGRI Talking Glossary, “Recessive.” ↩︎
- Bird, “Charcot-Marie-Tooth Hereditary Neuropathy Overview,” GeneReviews (rev. 2025), NCBI Bookshelf. ↩︎
- NINDS, “Charcot-Marie-Tooth Disease” (reviewed 2026). ↩︎
- Bird, “Charcot-Marie-Tooth Hereditary Neuropathy Overview,” GeneReviews (rev. 2025), NCBI Bookshelf. ↩︎
- Cleveland Clinic, “BiPAP.” ↩︎
- McCorquodale et al., “Management of Charcot-Marie-Tooth Disease,” J Multidiscip Healthc (2016), doi. ↩︎
- McKim et al., “Home Mechanical Ventilation: A Canadian Thoracic Society Clinical Practice Guideline,” Can Respir J (2011), doi. ↩︎
- NCI Dictionary of Cancer Terms, “single-blind study.” ↩︎
- NCI Dictionary of Cancer Terms, “double-blind study.” ↩︎
- Canadian Neuromuscular Disease Registry, home page. ↩︎
- MedlinePlus Genetics, “Charcot-Marie-Tooth Disease.” ↩︎
- MedlinePlus Genetics, “Charcot-Marie-Tooth Disease.” ↩︎
- NINDS, “Charcot-Marie-Tooth Disease” (reviewed 2026). ↩︎
- NINDS, “Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).” ↩︎
- ClinGen, accessed October 13, 2026, https://clinicalgenome.org/; Natasha T. Strande et al., “Evaluating the Clinical Validity of Gene-Disease Associations,” American Journal of Human Genetics 100, no. 6 (2017): 895–906, https://doi.org/10.1016/j.ajhg.2017.04.015. ↩︎
- NCI Dictionary of Cancer Terms, “clinical trial.” ↩︎
- Charcot–Marie–Tooth Association, “About CMTA.” ↩︎
- Inherited Neuropathy Consortium, home page. ↩︎
- Murphy et al., “Reliability of the CMT Neuropathy Score (Second Version),” J Peripher Nerv Syst (2011), doi. ↩︎
- Fridman et al., “A Longitudinal Study of CMT1A Using Rasch Analysis Based CMT Neuropathy and Examination Scores,” Neurology (2020), doi. ↩︎
- Mandarakas et al., “Multicenter Validation of the Charcot-Marie-Tooth Functional Outcome Measure,” Neurology (2024), doi. ↩︎
- Johnson et al., “The Charcot-Marie-Tooth Health Index,” Annals of Neurology (2018), doi. ↩︎
- Murphy et al., “Reliability of the CMT Neuropathy Score (Second Version),” J Peripher Nerv Syst (2011), doi. ↩︎
- Bird, “Charcot-Marie-Tooth Hereditary Neuropathy Overview,” GeneReviews (rev. 2025), NCBI Bookshelf. ↩︎
- NINDS, “Charcot-Marie-Tooth Disease” (reviewed 2026). ↩︎
- Bird, “Charcot-Marie-Tooth Hereditary Neuropathy Overview,” GeneReviews (rev. 2025), NCBI Bookshelf. ↩︎
- NINDS, “Charcot-Marie-Tooth Disease” (reviewed 2026). ↩︎
- Bird, “Charcot-Marie-Tooth Hereditary Neuropathy Overview,” GeneReviews (rev. 2025), NCBI Bookshelf. ↩︎
- NINDS, “Charcot-Marie-Tooth Disease” (reviewed 2026). ↩︎
- MedlinePlus Genetics, “MFN2 Gene.” ↩︎
- Bird, “Charcot-Marie-Tooth Hereditary Neuropathy Overview,” GeneReviews (rev. 2025), NCBI Bookshelf. ↩︎
- Bird, “Charcot-Marie-Tooth Hereditary Neuropathy Overview,” GeneReviews (rev. 2025), NCBI Bookshelf. ↩︎
- NINDS, “Charcot-Marie-Tooth Disease” (reviewed 2026). ↩︎
- MedlinePlus Genetics, “GJB1 Gene.” ↩︎
- NINDS, “Charcot-Marie-Tooth Disease” (reviewed 2026). ↩︎
- Bird, “Charcot-Marie-Tooth Hereditary Neuropathy Overview,” GeneReviews (rev. 2025), NCBI Bookshelf. ↩︎
- eCFR, “21 CFR 314.110, Complete Response Letter to the Applicant.” ↩︎
- Cole, “FDA Publishes More Than 200 Complete Response Letters,” Pharmaceutical Technology (2025). ↩︎
- Kafer, Feminist, Queer, Crip (Indiana University Press, 2013). ↩︎
- Samuels, “Six Ways of Looking at Crip Time,” Disability Studies Quarterly (2017). ↩︎
- NHGRI Talking Glossary, “CRISPR.” ↩︎
- NINDS, “Charcot-Marie-Tooth Disease” (reviewed 2026). ↩︎
- Bird, “Charcot-Marie-Tooth Hereditary Neuropathy Overview,” GeneReviews (rev. 2025), NCBI Bookshelf. ↩︎
- Sins Invalid, “10 Principles of Disability Justice.” ↩︎
- Canada Revenue Agency, “Disability Tax Credit (DTC).” ↩︎
- MeSH, “Disease” (D004194). ↩︎
- Mondo Disease Ontology, “disease” (MONDO:0000001). ↩︎
- Scheuermann, Ceusters and Smith, “Toward an Ontological Treatment of Disease and Diagnosis,” Summit on Translational Bioinformatics (2009). ↩︎
- Scheuermann, Ceusters and Smith, “Toward an Ontological Treatment of Disease and Diagnosis,” Summit on Translational Bioinformatics (2009). ↩︎
- NCI Thesaurus, “Disease or Disorder” (C2991). ↩︎
- MedlinePlus Genetics, “Charcot-Marie-Tooth Disease.” ↩︎
- Bird, “Charcot-Marie-Tooth Hereditary Neuropathy Overview,” GeneReviews (rev. 2025), NCBI Bookshelf. ↩︎
- Scheuermann, Ceusters and Smith, “Toward an Ontological Treatment of Disease and Diagnosis,” Summit on Translational Bioinformatics (2009). ↩︎
- MeSH, “Syndrome” (D013577). ↩︎
- Bird, “Charcot-Marie-Tooth Hereditary Neuropathy Overview,” GeneReviews (rev. 2025), NCBI Bookshelf. ↩︎
- Magy et al., “Updating the Classification of Inherited Neuropathies,” Neurology (2018), doi. ↩︎
- Pushpakom et al., “Drug Repurposing: Progress, Challenges and Recommendations,” Nat Rev Drug Discov (2019), doi. ↩︎
- NHGRI Talking Glossary, “Duplication.” ↩︎
- Bird, “Charcot-Marie-Tooth Hereditary Neuropathy Overview,” GeneReviews (rev. 2025), NCBI Bookshelf. ↩︎
- MedlinePlus, “Electromyography.” ↩︎
- NCI Dictionary of Cancer Terms, “endpoint.” ↩︎
- NHGRI Talking Glossary, “Exome.” ↩︎
- Bird, “Charcot-Marie-Tooth Hereditary Neuropathy Overview,” GeneReviews (rev. 2025), NCBI Bookshelf. ↩︎
- NINDS, “Charcot-Marie-Tooth Disease” (reviewed 2026). ↩︎
- FDA, “What Is Gene Therapy?” ↩︎
- NHGRI Talking Glossary, “Gene Therapy.” ↩︎
- FDA, “What Is Gene Therapy?” ↩︎
- Bird, “Charcot-Marie-Tooth Hereditary Neuropathy Overview,” GeneReviews (rev. 2025), NCBI Bookshelf. ↩︎
- NHGRI Talking Glossary, “Genetic Counseling.” ↩︎
- Bird, “Charcot-Marie-Tooth Hereditary Neuropathy Overview,” GeneReviews (rev. 2025), NCBI Bookshelf. ↩︎
- NHGRI Talking Glossary, “Genetics.” ↩︎
- NHGRI Talking Glossary, “Genetic Testing.” ↩︎
- MedlinePlus, “Hammer Toe.” ↩︎
- NINDS, “Charcot-Marie-Tooth Disease” (reviewed 2026). ↩︎
- Bird, “Charcot-Marie-Tooth Hereditary Neuropathy Overview,” GeneReviews (rev. 2025), NCBI Bookshelf. ↩︎
- Hereditary Neuropathy Foundation, HNF / CureCMT (home page). ↩︎
- MedlinePlus Genetics, “Hereditary Neuropathy with Liability to Pressure Palsies.” ↩︎
- MedlinePlus Genetics, “Hereditary Neuropathy with Liability to Pressure Palsies.” ↩︎
- Bird, “Charcot-Marie-Tooth Hereditary Neuropathy Overview,” GeneReviews (rev. 2025), NCBI Bookshelf. ↩︎
- Bird, “Charcot-Marie-Tooth Hereditary Neuropathy Overview,” GeneReviews (rev. 2025), NCBI Bookshelf. ↩︎
- HUGO Gene Nomenclature Committee, accessed October 13, 2026, https://www.genenames.org/. ↩︎
- NCI Dictionary of Cancer Terms, “idiopathic.” ↩︎
- Inherited Neuropathy Consortium, home page. ↩︎
- Bird, “Charcot-Marie-Tooth Hereditary Neuropathy Overview,” GeneReviews (rev. 2025), NCBI Bookshelf. ↩︎
- Berciano et al., “Intermediate Charcot-Marie-Tooth Disease: An Electrophysiological Reappraisal and Systematic Review,” J Neurol (2017), doi. ↩︎
- Chung and Boyle, “KIF1A-Related Neurodevelopmental Disorder,” GeneReviews (2026), NCBI Bookshelf. ↩︎
- Chung and Boyle, “KIF1A-Related Neurodevelopmental Disorder,” GeneReviews (2026), NCBI Bookshelf. ↩︎
- van Duijnhoven et al., “Specialized Orthotic Care to Improve Functioning in Adults with Neuromuscular Disorders,” Eur J Phys Rehabil Med (2025), doi. ↩︎
- McCorquodale et al., “Management of Charcot-Marie-Tooth Disease,” J Multidiscip Healthc (2016), doi. ↩︎
- Schellenberg et al., “Implementation of a Neuromuscular Clinical Trial Network,” Orphanet J Rare Dis (2026), doi. ↩︎
- Mondo Disease Ontology, accessed October 13, 2026, https://mondo.monarchinitiative.org/; Nicole A. Vasilevsky et al., “Mondo: Integrating Disease Terminology across Communities,” Genetics 232, no. 4 (2026): iyaf215, https://doi.org/10.1093/genetics/iyaf215. ↩︎
- Bird, “Charcot-Marie-Tooth Hereditary Neuropathy Overview,” GeneReviews (rev. 2025), NCBI Bookshelf. ↩︎
- Muscular Dystrophy Canada, home page. ↩︎
- NCI Dictionary of Cancer Terms, “natural history study.” ↩︎
- FDA, “Rare Diseases: Natural History Studies for Drug Development” (draft guidance, 2019). ↩︎
- Eichinger et al., “Accelerate Clinical Trials in Charcot-Marie-Tooth Disease (ACT-CMT),” Frontiers in Neurology (2022), doi. ↩︎
- MedlinePlus, “Nerve Conduction Velocity.” ↩︎
- Bird, “Charcot-Marie-Tooth Hereditary Neuropathy Overview,” GeneReviews (rev. 2025), NCBI Bookshelf. ↩︎
- MedlinePlus, “Obstructive Sleep Apnea – Adults.” ↩︎
- NCI Dictionary of Cancer Terms, “open label study.” ↩︎
- NCI Dictionary of Cancer Terms, “orphan drug.” US Food and Drug Administration, “Designating an Orphan Product: Drugs and Biological Products.” ↩︎
- Graham and Hughes, “A Modified Peripheral Neuropathy Scale: The Overall Neuropathy Limitations Scale,” JNNP (2006), doi. ↩︎
- NCI Dictionary of Cancer Terms, “peripheral neuropathy.” ↩︎
- MedlinePlus, “Sensorimotor Polyneuropathy.” ↩︎
- Bird, “Charcot-Marie-Tooth Hereditary Neuropathy Overview,” GeneReviews (rev. 2025), NCBI Bookshelf. ↩︎
- FDA, “Step 3: Clinical Research.” ↩︎
- NHGRI Talking Glossary, “Phenotype.” ↩︎
- Bird, “Charcot-Marie-Tooth Hereditary Neuropathy Overview,” GeneReviews (rev. 2025), NCBI Bookshelf. ↩︎
- NCI Dictionary of Cancer Terms, “phrenic nerve.” ↩︎
- NCI Dictionary of Cancer Terms, “placebo.” ↩︎
- NHGRI Talking Glossary, “Plasmid.” ↩︎
- FDA, “What Is Gene Therapy?” ↩︎
- US Food and Drug Administration, Considerations for the Use of the Plausible Mechanism Framework, draft guidance (February 2026). ↩︎
- Abrams et al., “Clinical Development of Therapies for Charcot–Marie–Tooth Disease,” J Peripher Nerv Syst (2026), doi. ↩︎
- Attarian et al., “A Double-Blind, Placebo-Controlled, Randomized Trial of PXT3003,” Orphanet J Rare Dis (2021), doi. ↩︎
- MedlinePlus Genetics, “PMP22 Gene.” ↩︎
- 21 U.S.C. § 360ff. US Food and Drug Administration, “Priority Review.” ↩︎
- US Government Accountability Office, Drug Development: FDA’s Priority Review Voucher Programs, GAO-20-251 (2020). ↩︎
- NCI Dictionary of Cancer Terms, “quality of life.” ↩︎
- NCI Dictionary of Cancer Terms, “patient-reported outcome.” ↩︎
- McCorquodale et al., “Management of Charcot-Marie-Tooth Disease,” J Multidiscip Healthc (2016), doi. ↩︎
- NHGRI Talking Glossary, “X-Linked.” ↩︎
- Bird, “Charcot-Marie-Tooth Hereditary Neuropathy Overview,” GeneReviews (rev. 2025), NCBI Bookshelf. ↩︎
- NCI Dictionary of Cancer Terms, “randomized clinical trial.” ↩︎
- FDA, “Rare Diseases at FDA.” ↩︎
- Health Canada, “Building a National Strategy for High-Cost Drugs for Rare Diseases” (2021). ↩︎
- MedlinePlus Genetics, “Charcot-Marie-Tooth Disease.” ↩︎
- 21 U.S.C. § 360ff. ↩︎
- NCI Dictionary of Cancer Terms, “diaphragm.” ↩︎
- NCI Dictionary of Cancer Terms, “pulmonary function test.” ↩︎
- Garcez et al., “Evaluation of Respiratory Muscle Strength and Pulmonary Function in Patients with Charcot-Marie-Tooth Disease Type 2,” Eur Neurol (2015), doi. ↩︎
- NCI Dictionary of Cancer Terms, “Schwann cell.” ↩︎
- MedlinePlus Genetics, “PMP22 Gene.” ↩︎
- Human Phenotype Ontology, “Semidominant inheritance” (HP:0032113), accessed October 13, 2026, https://hpo.jax.org/browse/term/HP:0032113. ↩︎
- Cortese et al., “Biallelic Mutations in SORD Cause a Common and Potentially Treatable Hereditary Neuropathy,” Nature Genetics (2020), doi. ↩︎
- Bird, “Charcot-Marie-Tooth Hereditary Neuropathy Overview,” GeneReviews (rev. 2025), NCBI Bookshelf. ↩︎
- MedlinePlus Genetics, “Spinal Muscular Atrophy.” ↩︎
- NCI Dictionary of Genetics Terms, “splice-site variant.” ↩︎
- Smieszek et al., “Potential ASO-Based Personalized Treatment for Charcot-Marie-Tooth Disease Type 2S,” Mol Ther Nucleic Acids (2025), doi. ↩︎
- Miserandino, “The Spoon Theory” (2003). ↩︎
- FDA, “Surrogate Endpoint Resources for Drug and Biologic Development.” ↩︎
- Dreher et al., “Surgical Treatment of Severe Cavovarus Foot Deformity in Charcot-Marie-Tooth Disease,” JBJS Essent Surg Tech (2015), doi. ↩︎
- McCorquodale et al., “Management of Charcot-Marie-Tooth Disease,” J Multidiscip Healthc (2016), doi. ↩︎
- NCI Dictionary of Cancer Terms, “translational research.” ↩︎
- NINDS, “Motor Neuron Diseases.” ↩︎
- MedlinePlus Genetics, “What Do the Results of Genetic Tests Mean?” ↩︎
- NCI Dictionary of Cancer Terms, “whole genome sequencing.” ↩︎
- Bird, “Charcot-Marie-Tooth Hereditary Neuropathy Overview,” GeneReviews (rev. 2025), NCBI Bookshelf. ↩︎
Bibliography
- “21 CFR 314.110 Complete Response Letter to the Applicant.” Electronic Code of Federal Regulations. Accessed October 23, 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314/subpart-D/section-314.110.
- Abrams, Charles K., Sue Bruhn, Joshua Burns, et al. “Clinical Development of Therapies for Charcot–Marie–Tooth Disease: Recommendations for Trial Design, Endpoints, and Regulatory Pathways.” Journal of the Peripheral Nervous System 31, no. 3 (2026): e70146. https://doi.org/10.1111/jns.70146.
- Attarian, Shahram, Peter Young, Thomas H. Brannagan, et al. “A Double-Blind, Placebo-Controlled, Randomized Trial of PXT3003 for the Treatment of Charcot–Marie–Tooth Type 1A.” Orphanet Journal of Rare Diseases 16, no. 1 (2021): 433. https://doi.org/10.1186/s13023-021-02040-8.
- Berciano, José, Antonio García, Elena Gallardo, et al. “Intermediate Charcot-Marie-Tooth Disease: An Electrophysiological Reappraisal and Systematic Review.” Journal of Neurology 264, no. 8 (2017): 1655–1677. https://doi.org/10.1007/s00415-017-8474-3.
- Bird, Thomas D. “Charcot-Marie-Tooth Hereditary Neuropathy Overview.” GeneReviews. November 20, 2025. https://www.ncbi.nlm.nih.gov/books/NBK1358/.
- Canada Revenue Agency. “Disability Tax Credit (DTC).” Accessed October 10, 2026. https://www.canada.ca/en/revenue-agency/services/tax/individuals/segments/tax-credits-deductions-persons-disabilities/disability-tax-credit.html.
- Canadian Neuromuscular Disease Registry. “Home.” Accessed October 10, 2026. https://cndr.org/.
- Charcot-Marie-Tooth Association. “About CMTA.” Accessed October 10, 2026. https://www.cmtausa.org/about-us/.
- Chung, Wendy, and Lia Boyle. “KIF1A-Related Neurodevelopmental Disorder.” GeneReviews. April 2, 2026. https://www.ncbi.nlm.nih.gov/books/NBK621569/.
- Cleveland Clinic. “BiPAP.” Cleveland Clinic Health Library. Accessed October 13, 2026. https://my.clevelandclinic.org/health/treatments/24970-bipap.
- Cole, Christopher. “FDA Publishes More Than 200 Complete Response Letters.” Pharmaceutical Technology, July 11, 2025. https://www.pharmtech.com/view/fda-publishes-more-than-200-complete-response-letters.
- Cortese, Andrea, Yi Zhu, Adriana P. Rebelo, et al. “Biallelic Mutations in SORD Cause a Common and Potentially Treatable Hereditary Neuropathy with Implications for Diabetes.” Nature Genetics 52, no. 5 (2020): 473–481. https://doi.org/10.1038/s41588-020-0615-4.
- Dreher, Thomas, Nicholas A. Beckmann, and Wolfram Wenz. “Surgical Treatment of Severe Cavovarus Foot Deformity in Charcot-Marie-Tooth Disease.” JBJS Essential Surgical Techniques 5, no. 2 (2015): e11. https://doi.org/10.2106/JBJS.ST.N.00005.
- Duijnhoven, Elza van, Fieke S. Koopman, Jana Tuijtelaars, et al. “Specialized Orthotic Care to Improve Functioning in Adults with Neuromuscular Disorders: Results of an Open-Label Blinded End-Point Randomized Controlled Trial.” European Journal of Physical and Rehabilitation Medicine 61, no. 3 (2025): 496–508. https://doi.org/10.23736/S1973-9087.25.08770-2.
- Eichinger, Katy, Janet E. Sowden, Joshua Burns, et al. “Accelerate Clinical Trials in Charcot-Marie-Tooth Disease (ACT-CMT): A Protocol to Address Clinical Trial Readiness in CMT1A.” Frontiers in Neurology 13 (June 2022): 930435. https://doi.org/10.3389/fneur.2022.930435.
- Fridman, Vera, Stefan Sillau, Gyula Acsadi, et al. “A Longitudinal Study of CMT1A Using Rasch Analysis Based CMT Neuropathy and Examination Scores.” Neurology 94, no. 9 (2020): e884–e896. https://doi.org/10.1212/WNL.0000000000009035.
- Garcez, Catarina Andrade, Eduardo Luis Aquino Neves, Saulo Maia D’Ávila Melo, et al. “Evaluation of Respiratory Muscle Strength and Pulmonary Function in Patients with Charcot-Marie-Tooth Disease Type 2.” European Neurology 74, no. 5-6 (2015): 310–314. https://doi.org/10.1159/000442282.
- Graham, R. C., and R. A. C. Hughes. “A Modified Peripheral Neuropathy Scale: The Overall Neuropathy Limitations Scale.” Journal of Neurology, Neurosurgery & Psychiatry 77, no. 8 (2006): 973–976. https://doi.org/10.1136/jnnp.2005.081547.
- Health Canada. Building a National Strategy for High-Cost Drugs for Rare Diseases: A Discussion Paper for Engaging Canadians. 2021. https://www.canada.ca/en/health-canada/programs/consultation-national-strategy-high-cost-drugs-rare-diseases-online-engagement/discussion-paper.html.
- Hereditary Neuropathy Foundation. “HNF / CureCMT.” Accessed October 10, 2026. https://curecmt.org/.
- “Inherited Neuropathy Consortium.” Rare Diseases Clinical Research Network. Accessed October 10, 2026. https://www.rarediseasesnetwork.org/inc.
- Johnson, Nicholas E., Chad Heatwole, Peter Creigh, et al. “The Charcot-Marie-Tooth Health Index: Evaluation of a Patient-Reported Outcome.” Annals of Neurology 84, no. 2 (2018): 225–233. https://doi.org/10.1002/ana.25282.
- Kafer, Alison. Feminist, Queer, Crip. Indiana University Press, 2013.
- Legal Information Institute. 21 U.S.C. § 360ff, Priority Review to Encourage Treatments for Rare Pediatric Diseases. Accessed October 13, 2026. https://www.law.cornell.edu/uscode/text/21/360ff.
- Magy, Laurent, Stéphane Mathis, Gwendal Le Masson, Cyril Goizet, Meriem Tazir, and Jean-Michel Vallat. “Updating the Classification of Inherited Neuropathies: Results of an International Survey.” Neurology 90, no. 10 (2018): e870–e876. https://doi.org/10.1212/WNL.0000000000005074.
- Mandarakas, Melissa R., Katy J. Eichinger, Paula Bray, et al. “Multicenter Validation of the Charcot-Marie-Tooth Functional Outcome Measure.” Neurology 102, no. 3 (2024): e207963. https://doi.org/10.1212/WNL.0000000000207963.
- McCorquodale, Donald, Evan M. Pucillo, and Nicholas E. Johnson. “Management of Charcot-Marie-Tooth Disease: Improving Long-Term Care with a Multidisciplinary Approach.” Journal of Multidisciplinary Healthcare 9 (2016): 7–19. https://doi.org/10.2147/JMDH.S69979.
- McKim, Douglas A., Jeremy Road, Monica Avendano, et al. “Home Mechanical Ventilation: A Canadian Thoracic Society Clinical Practice Guideline.” Canadian Respiratory Journal 18, no. 4 (2011): 197–215. https://doi.org/10.1155/2011/139769.
- MedlinePlus Genetics. “Charcot-Marie-Tooth Disease.” MedlinePlus. Accessed October 10, 2026. https://medlineplus.gov/genetics/condition/charcot-marie-tooth-disease/.
- MedlinePlus Genetics. “GJB1 Gene.” MedlinePlus. Accessed October 10, 2026. https://medlineplus.gov/genetics/gene/gjb1/.
- MedlinePlus Genetics. “Hereditary Neuropathy with Liability to Pressure Palsies.” MedlinePlus. Accessed October 10, 2026. https://medlineplus.gov/genetics/condition/hereditary-neuropathy-with-liability-to-pressure-palsies/.
- MedlinePlus Genetics. “MFN2 Gene.” MedlinePlus. Accessed October 10, 2026. https://medlineplus.gov/genetics/gene/mfn2/.
- MedlinePlus Genetics. “PMP22 Gene.” MedlinePlus. Accessed October 10, 2026. https://medlineplus.gov/genetics/gene/pmp22/.
- MedlinePlus Genetics. “Spinal Muscular Atrophy.” MedlinePlus. Accessed October 10, 2026. https://medlineplus.gov/genetics/condition/spinal-muscular-atrophy/.
- MedlinePlus Genetics. “What Do the Results of Genetic Tests Mean?” MedlinePlus. Accessed October 10, 2026. https://medlineplus.gov/genetics/understanding/testing/interpretingresults/.
- MedlinePlus Medical Encyclopedia. “Electromyography.” MedlinePlus. Accessed October 10, 2026. https://medlineplus.gov/ency/article/003929.htm.
- MedlinePlus Medical Encyclopedia. “Hammer Toe.” MedlinePlus. Accessed October 10, 2026. https://medlineplus.gov/ency/article/001235.htm.
- MedlinePlus Medical Encyclopedia. “Nerve Conduction Velocity.” MedlinePlus. Accessed October 10, 2026. https://medlineplus.gov/ency/article/003927.htm.
- MedlinePlus Medical Encyclopedia. “Obstructive Sleep Apnea – Adults.” MedlinePlus. Accessed October 10, 2026. https://medlineplus.gov/ency/article/000811.htm.
- MedlinePlus Medical Encyclopedia. “Sensorimotor Polyneuropathy.” MedlinePlus. Accessed October 10, 2026. https://medlineplus.gov/ency/article/000750.htm.
- Miserandino, Christine. “The Spoon Theory.” But You Don’t Look Sick. 2003. https://butyoudontlooksick.com/articles/written-by-christine/the-spoon-theory/.
- Monarch Initiative. “disease (MONDO:0000001).” Mondo Disease Ontology. Accessed October 10, 2026. https://purl.obolibrary.org/obo/MONDO_0000001.
- Murphy, Sinéad M., David N. Herrmann, Michael P. McDermott, et al. “Reliability of the CMT Neuropathy Score (Second Version) in Charcot-Marie-Tooth Disease.” Journal of the Peripheral Nervous System 16, no. 3 (2011): 191–198. https://doi.org/10.1111/j.1529-8027.2011.00350.x.
- Muscular Dystrophy Canada. “Home.” Accessed October 10, 2026. https://muscle.ca/.
- National Cancer Institute. “antisense oligonucleotide.” NCI Dictionary of Cancer Terms. Accessed October 10, 2026. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/antisense-oligonucleotide.
- National Cancer Institute. “autonomic nervous system.” NCI Dictionary of Cancer Terms. Accessed October 10, 2026. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/autonomic-nervous-system.
- National Cancer Institute. “clinical trial.” NCI Dictionary of Cancer Terms. Accessed October 10, 2026. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/clinical-trial.
- National Cancer Institute. “diaphragm.” NCI Dictionary of Cancer Terms. Accessed October 10, 2026. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/diaphragm.
- National Cancer Institute. “Disease or Disorder.” NCI Thesaurus. Accessed October 10, 2026. https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2991.
- National Cancer Institute. “double-blind study.” NCI Dictionary of Cancer Terms. Accessed October 13, 2026. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/double-blind-study.
- National Cancer Institute. “endpoint.” NCI Dictionary of Cancer Terms. Accessed October 10, 2026. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/endpoint.
- National Cancer Institute. “idiopathic.” NCI Dictionary of Cancer Terms. Accessed October 10, 2026. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/idiopathic.
- National Cancer Institute. “natural history study.” NCI Dictionary of Cancer Terms. Accessed October 10, 2026. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/natural-history-study.
- National Cancer Institute. “open label study.” NCI Dictionary of Cancer Terms. Accessed October 10, 2026. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/open-label-study.
- National Cancer Institute. “orphan drug.” NCI Dictionary of Cancer Terms. Accessed October 23, 2026. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/orphan-drug.
- National Cancer Institute. “patient-reported outcome.” NCI Dictionary of Cancer Terms. Accessed October 13, 2026. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/patient-reported-outcome.
- National Cancer Institute. “peripheral neuropathy.” NCI Dictionary of Cancer Terms. Accessed October 10, 2026. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/peripheral-neuropathy.
- National Cancer Institute. “phrenic nerve.” NCI Dictionary of Cancer Terms. Accessed October 10, 2026. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/phrenic-nerve.
- National Cancer Institute. “placebo.” NCI Dictionary of Cancer Terms. Accessed October 10, 2026. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/placebo.
- National Cancer Institute. “pulmonary function test.” NCI Dictionary of Cancer Terms. Accessed October 10, 2026. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/pulmonary-function-test.
- National Cancer Institute. “quality of life.” NCI Dictionary of Cancer Terms. Accessed October 13, 2026. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/quality-of-life.
- National Cancer Institute. “randomized clinical trial.” NCI Dictionary of Cancer Terms. Accessed October 10, 2026. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/randomized-clinical-trial.
- National Cancer Institute. “Schwann cell.” NCI Dictionary of Cancer Terms. Accessed October 10, 2026. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/schwann-cell.
- National Cancer Institute. “single-blind study.” NCI Dictionary of Cancer Terms. Accessed October 13, 2026. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/single-blind-study.
- National Cancer Institute. “splice-site variant.” NCI Dictionary of Genetics Terms. Accessed October 23, 2026. https://www.cancer.gov/publications/dictionaries/genetics-dictionary/def/splice-site-variant.
- National Cancer Institute. “translational research.” NCI Dictionary of Cancer Terms. Accessed October 13, 2026. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/translational-research.
- National Cancer Institute. “whole genome sequencing.” NCI Dictionary of Cancer Terms. Accessed October 13, 2026. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/whole-genome-sequencing.
- National Human Genome Research Institute. “Autosomal Dominant.” Talking Glossary of Genomic and Genetic Terms. Accessed October 10, 2026. https://www.genome.gov/genetics-glossary/Autosomal-Dominant.
- National Human Genome Research Institute. “CRISPR.” Talking Glossary of Genomic and Genetic Terms. Accessed October 10, 2026. https://www.genome.gov/genetics-glossary/CRISPR.
- National Human Genome Research Institute. “Duplication.” Talking Glossary of Genomic and Genetic Terms. Accessed October 10, 2026. https://www.genome.gov/genetics-glossary/Duplication.
- National Human Genome Research Institute. “Exome.” Talking Glossary of Genomic and Genetic Terms. Accessed October 10, 2026. https://www.genome.gov/genetics-glossary/Exome.
- National Human Genome Research Institute. “Gene Therapy.” Talking Glossary of Genomic and Genetic Terms. Accessed October 10, 2026. https://www.genome.gov/genetics-glossary/Gene-Therapy.
- National Human Genome Research Institute. “Genetic Counseling.” Talking Glossary of Genomic and Genetic Terms. Accessed October 10, 2026. https://www.genome.gov/genetics-glossary/Genetic-Counseling.
- National Human Genome Research Institute. “Genetic Testing.” Talking Glossary of Genomic and Genetic Terms. Accessed October 10, 2026. https://www.genome.gov/genetics-glossary/Genetic-Testing.
- National Human Genome Research Institute. “Genetics.” Talking Glossary of Genomic and Genetic Terms. Accessed October 10, 2026. https://www.genome.gov/genetics-glossary/Genetics.
- National Human Genome Research Institute. “Phenotype.” Talking Glossary of Genomic and Genetic Terms. Accessed October 10, 2026. https://www.genome.gov/genetics-glossary/Phenotype.
- National Human Genome Research Institute. “Plasmid.” Talking Glossary of Genomic and Genetic Terms. Accessed October 10, 2026. https://www.genome.gov/genetics-glossary/Plasmid.
- National Human Genome Research Institute. “Recessive.” Talking Glossary of Genomic and Genetic Terms. Accessed October 10, 2026. https://www.genome.gov/genetics-glossary/Recessive.
- National Human Genome Research Institute. “X-Linked.” Talking Glossary of Genomic and Genetic Terms. Accessed October 10, 2026. https://www.genome.gov/genetics-glossary/X-Linked.
- National Institute of Neurological Disorders and Stroke. “Charcot-Marie-Tooth Disease.” September 2, 2026. https://www.ninds.nih.gov/health-information/disorders/charcot-marie-tooth-disease.
- National Institute of Neurological Disorders and Stroke. “Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).” Accessed October 10, 2026. https://www.ninds.nih.gov/health-information/disorders/chronic-inflammatory-demyelinating-polyneuropathy-cidp.
- National Institute of Neurological Disorders and Stroke. “Motor Neuron Diseases.” Accessed October 13, 2026. https://www.ninds.nih.gov/health-information/disorders/motor-neuron-diseases.
- National Library of Medicine. “Disease.” Medical Subject Headings (MeSH). Accessed October 10, 2026. https://meshb.nlm.nih.gov/record/ui?ui=D004194.
- National Library of Medicine. “Syndrome.” Medical Subject Headings (MeSH). Accessed October 10, 2026. https://meshb.nlm.nih.gov/record/ui?ui=D013577.
- Pushpakom, Sudeep, Francesco Iorio, Patrick A. Eyers, et al. “Drug Repurposing: Progress, Challenges and Recommendations.” Nature Reviews Drug Discovery 18, no. 1 (2019): 41–58. https://doi.org/10.1038/nrd.2018.168.
- Samuels, Ellen. “Six Ways of Looking at Crip Time.” Disability Studies Quarterly 37, no. 3 (2017). https://doi.org/10.18061/dsq.v37i3.5824.
- Schellenberg, Kerri Lynn, Homira Osman, Maria Masnata, et al. “Implementation of a Neuromuscular Clinical Trial Network: A Rare Disease Model for Enhancing Clinical Trial Readiness, Capacity, and Access in Canada.” Orphanet Journal of Rare Diseases 21, no. 1 (2026): 252. https://doi.org/10.1186/s13023-026-04393-4.
- Scheuermann, Richard H., Werner Ceusters, and Barry Smith. “Toward an Ontological Treatment of Disease and Diagnosis.” Summit on Translational Bioinformatics (March 2009): 116–120. https://pmc.ncbi.nlm.nih.gov/articles/PMC3041577/.
- Sins Invalid. “10 Principles of Disability Justice.” Accessed October 10, 2026. https://sinsinvalid.org/10-principles-of-disability-justice/.
- Smieszek, Sandra P., et al. “Potential ASO-Based Personalized Treatment for Charcot-Marie-Tooth Disease Type 2S.” Molecular Therapy Nucleic Acids 36, no. 1 (2025): 102479. https://doi.org/10.1016/j.omtn.2025.102479.
- U.S. Food and Drug Administration. “Accelerated Approval Program.” Accessed October 23, 2026. https://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approval-program.
- US Food and Drug Administration. Considerations for the Use of the Plausible Mechanism Framework (Draft Guidance for Industry). February 2026. https://www.fda.gov/media/191247/download.
- US Food and Drug Administration. “Designating an Orphan Product: Drugs and Biological Products.” Accessed October 23, 2026. https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products.
- US Food and Drug Administration. “Priority Review.” Accessed October 13, 2026. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/priority-review.
- US Food and Drug Administration. “Rare Diseases at FDA.” Accessed October 10, 2026. https://www.fda.gov/patients/rare-diseases-fda.
- US Food and Drug Administration. Rare Diseases: Natural History Studies for Drug Development. Docket FDA-2019-D-0481. 2019. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rare-diseases-natural-history-studies-drug-development.
- US Food and Drug Administration. “Step 3: Clinical Research.” The Drug Development Process. Accessed October 10, 2026. https://www.fda.gov/patients/drug-development-process/step-3-clinical-research.
- US Food and Drug Administration. “Surrogate Endpoint Resources for Drug and Biologic Development.” Accessed October 10, 2026. https://www.fda.gov/drugs/development-resources/surrogate-endpoint-resources-drug-and-biologic-development.
- US Food and Drug Administration. “What Is Gene Therapy?” Accessed October 10, 2026. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/what-gene-therapy.
- US Government Accountability Office. Drug Development: FDA’s Priority Review Voucher Programs (GAO-20-251). January 31, 2020. https://www.gao.gov/products/gao-20-251.
- Zhao, Hien Tran, Sagar Damle, Karli Ikeda-Lee, et al. “PMP22 Antisense Oligonucleotides Reverse Charcot-Marie-Tooth Disease Type 1A Features in Rodent Models.” Journal of Clinical Investigation 128, no. 1 (2018): 359–368. https://doi.org/10.1172/JCI96499.
